Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.

ABSTRACT:

Importance

The comparative effectiveness of rivaroxaban and apixaban, the most frequently prescribed oral anticoagulants for ischemic stroke prevention in patients with atrial fibrillation, is uncertain.

Objective

To compare major ischemic and hemorrhagic outcomes in patients with atrial fibrillation treated with rivaroxaban or apixaban.

Design, setting, and participants

Retrospective cohort study using computerized enrollment and claims files for US Medicare beneficiaries 65 years or older. Between January 1, 2013, and November 30, 2018, a total of 581 451 patients with atrial fibrillation began rivaroxaban or apixaban treatment and were followed up for 4 years, through November 30, 2018.

Exposures

Rivaroxaban (n = 227 572) and apixaban (n = 353 879), either s

SUBMITTER: Ray WA 

PROVIDER: S-EPMC8693217 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature